Vyleesi Pre-Surgery Hold Window: What Patients and Prescribers Need to Know

What Is the Bremelanotide Pre-Surgery Hold Window?

The standard guidance is to skip bremelanotide on the day of elective surgery and, where scheduling allows, to skip the prior day's dose as well. This recommendation comes directly from the FDA prescribing information, which flags transient hypertension as a known adverse effect requiring clinical caution whenever cardiovascular stress is anticipated.

Because bremelanotide is used on an as-needed basis rather than on a fixed daily schedule, the "hold window" is less about a rigid taper and more about ensuring no dose falls within 24 hours of anesthesia induction. The active metabolite cyclo(CH2CO-His-DPhe-Arg-Trp-Lys), which forms after peptide cleavage, carries a half-life of roughly 20 hours, meaning residual pharmacodynamic activity can persist well past the point when patients feel the acute injection-site flush has resolved.

Why the FDA Flagged This in the Label

The FDA approved bremelanotide in June 2019 under NDA 210557. The full prescribing information lists "transient decreases in blood pressure", caused by a reflex response to the initial hypertensive spike, as a reason to avoid use in women with cardiovascular disease. The label explicitly states that bremelanotide "should not be used in women with cardiovascular disease" and that blood pressure returns to baseline within 12 hours. The surgical corollary follows directly: if a patient receives a dose within that 12-hour window and then undergoes general anesthesia, the anesthesiologist may face a labile hemodynamic baseline without knowing the cause.

The Pharmacokinetic Basis for a 24-Hour Margin

After a 1.75 mg subcutaneous injection, bremelanotide reaches peak plasma concentration (Cmax) within approximately 1 hour. The parent compound is eliminated with a terminal half-life of about 2.7 hours, which would suggest clearance within 12 to 15 hours. However, the FDA clinical pharmacology review identifies the cyclic peptide metabolite as pharmacologically active at melanocortin receptors, extending the functional duration of action. A conservative 24-hour hold from the last dose therefore provides roughly five to eight half-lives of the parent compound and at least one full half-life of the active metabolite before induction.

Cardiovascular Pharmacology: Why This Matters in the OR

Bremelanotide activates melanocortin receptors MC1R, MC3R, and MC4R. MC4R activation in the central nervous system modulates sexual arousal, but peripheral MC3R and MC4R activity produces vasoconstriction and sympathetic tone increases that translate into measurable blood-pressure elevation. A 2018 review in the Journal of Sexual Medicine outlined the cardiovascular signal observed across the development program: mean systolic increases of approximately 12 mmHg and diastolic increases of approximately 7 mmHg peaking within 60 minutes of each dose.

The RECONNECT Trial Data on Blood Pressure

The RECONNECT program, published in Obstetrics and Gynecology in 2019, enrolled 1,267 premenopausal women across two Phase 3 randomized controlled trials to evaluate bremelanotide 1.75 mg versus placebo [1]. The primary endpoints were changes in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm score at 24 weeks. Bremelanotide produced statistically significant improvements on both measures compared with placebo (P<0.001 on both co-primary endpoints). Nausea occurred in 40% of bremelanotide users versus 1% of placebo users.

Within the cardiovascular safety data reported alongside RECONNECT, the blood-pressure elevations were characterized as transient and self-limiting. No participant experienced a hypertensive emergency during the trial. However, all trial participants were pre-screened to exclude cardiovascular disease, which means the RECONNECT population does not represent the full real-world range of surgical candidates who might use Vyleesi.

Interaction with Common Anesthetic Agents

Volatile anesthetics such as sevoflurane and desflurane produce dose-dependent vasodilation and myocardial depression. Propofol induction similarly drops systemic vascular resistance by 25 to 40%. A patient who received bremelanotide within 12 hours of induction may arrive in the preoperative area with a blood pressure that has already been artificially elevated and is now crashing through the vasodilatory trough created by the anesthetic. The net effect on mean arterial pressure is hard to predict without knowing the exact time since dose.

Opioid premedication and neuraxial anesthesia carry their own hypotensive burdens. A 2021 review in Anesthesiology on drug-induced hemodynamic instability during general anesthesia identifies unrecognized vasoactive medications as a leading preventable cause of perioperative hypotension. Bremelanotide fits squarely in this category when the dosing history is not disclosed.

Clinical Significance in Specific Surgical Populations

Gynecologic and Reproductive Surgery

HSDD is the approved indication for bremelanotide, so the population most likely to be taking this drug overlaps substantially with women undergoing gynecologic procedures. Hysteroscopy, laparoscopic myomectomy, and endometrial ablation are common ambulatory procedures in premenopausal women. Anesthesia for these cases is frequently total intravenous anesthesia (TIVA) with propofol and remifentanil, a combination that can produce significant blood-pressure drops at induction. The ACOG Committee Opinion on preoperative evaluation recommends a complete medication list including "all prescription and over-the-counter drugs, supplements, and herbal preparations" prior to any surgical procedure, a category that explicitly covers hormone-active and peptide-based agents.

Cardiovascular and High-Risk Surgery

Women with cardiovascular risk factors are a more complicated subset. The FDA label contraindication against bremelanotide use in women with cardiovascular disease means a patient who is taking Vyleesi and has known hypertension or coronary artery disease is already off-label. Perioperative teams should note that the American Heart Association's 2014 perioperative cardiovascular guidelines, updated in subsequent focused updates, recommend managing all vasoactive medications with the treating cardiologist before non-cardiac surgery. Any drug capable of producing a 12 mmHg acute systolic rise warrants that same level of scrutiny.

Ambulatory and Same-Day Surgery

Same-day surgery presents a specific documentation challenge. Patients may not volunteer information about as-needed sexual health medications, and short preoperative intake windows leave little time to investigate. A 2020 analysis in JAMA Surgery found that medication reconciliation errors at ambulatory surgery centers affected nearly 30% of surgical cases, with hormonal and peptide medications among the most frequently omitted categories. A direct intake question about Vyleesi or bremelanotide is therefore clinically warranted at preoperative check-in.

Practical Hold-Window Protocol for Prescribers

The absence of a procedure-specific "hold X days before surgery" statement in the bremelanotide label differs from anticoagulants or antiplatelet agents, which have well-characterized bridging protocols. For bremelanotide, the protocol is simpler because the drug is not a daily chronic therapy.

The following stepwise approach reflects the pharmacokinetic data and FDA label language:

1. At the time of surgical scheduling, ask the patient directly whether she uses bremelanotide (Vyleesi) for HSDD.
2. If yes, confirm the last-use date. If the patient used bremelanotide within 24 hours of the planned procedure, notify the anesthesia team so they can plan hemodynamic monitoring accordingly.
3. Instruct the patient to skip any planned bremelanotide use for at least 24 hours before surgery. Given the approximately 20-hour active metabolite half-life, a 24-hour margin provides one full half-life of clearance. A 48-hour hold, where scheduling allows, provides a more conservative two half-lives.
4. Document the last-use time in the surgical pre-assessment note. This ensures the anesthesiologist has the information even if the patient forgets to mention it during the brief pre-induction interview.
5. Resume bremelanotide use after full postoperative recovery, once the patient has returned to baseline cardiovascular status and is no longer taking opioid analgesics that could compound orthostatic hypotension.

This framework aligns with the FDA labeling language available at the FDA prescribing information page and with general perioperative principles for vasoactive agents outlined by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation.

What Anesthesiologists Should Know

Anesthesiologists encountering a patient who took bremelanotide within 12 to 24 hours of induction should consider two phases of hemodynamic risk: an early hypertensive phase if the drug is still at peak effect, and a rebound orthostatic hypotensive phase as the drug clears during early recovery. The FDA MedWatch pharmacovigilance database has received reports of blood-pressure fluctuations associated with bremelanotide, though case-level data are not publicly disaggregated by surgical setting.

Monitoring Recommendations

For a patient with a same-day disclosure of recent bremelanotide use, consider:

• Baseline and induction blood-pressure monitoring at two-minute intervals rather than the standard five-minute perioperative interval.
• A phenylephrine infusion (rather than bolus ephedrine) as first-line vasopressor, given that phenylephrine's pure alpha-1 agonism offers more predictable blood-pressure titration against a background of already-active melanocortin-mediated sympathetic tone. A 2017 consensus statement from the Society for Obstetric Anesthesia and Perinatology supports phenylephrine as first-line for vasopressor management in cases of hemodynamic unpredictability, a principle applicable here by analogy.
• Arterial line placement for any case classified as intermediate or high cardiovascular risk.

Postoperative Recovery

The postanesthesia care unit (PACU) period is also relevant. Bremelanotide's active metabolite may still be circulating during recovery, and the combination of residual volatile anesthetic vasodilation, opioid analgesics, and active melanocortin receptor stimulation could produce atypical blood-pressure trajectories. PACU nurses should have the bremelanotide last-use time documented in the chart so they can contextualize blood-pressure readings that fall outside the normal postoperative range. Current ASPAN standards for PACU monitoring recommend continuous pulse oximetry and blood-pressure checks no less than every 15 minutes during Phase I recovery, a baseline that remains appropriate here.

Patient Communication: How to Explain the Hold to Your Patient

The clinical rationale above can be simplified for patients without losing accuracy. A script that works in practice:

"Vyleesi raises your blood pressure for a few hours after each dose. Anesthesia does the opposite. If those two things happen close together, your blood pressure can be harder to manage safely during your operation. So we ask you not to use Vyleesi for at least 24 hours before any surgery. When you're fully recovered afterward, you can start using it again."

Patients often ask whether this means they need to stop the drug permanently if they have multiple surgical procedures. The answer is no. Because bremelanotide is used only as-needed rather than daily, the management approach is simply to time each use away from any planned procedures.

The Endocrine Society's clinical practice guidance on female sexual dysfunction notes that shared decision-making about treatment timing is an expected component of prescribing any pharmacotherapy for HSDD, which includes counseling patients on practical scheduling considerations like surgical hold windows.

Drug-Drug Interactions Relevant to the Perioperative Context

The FDA label for bremelanotide notes a specific interaction with naltrexone: bremelanotide reduces the oral bioavailability of naltrexone by approximately 35%. Patients on naltrexone for alcohol use disorder or opioid use disorder who are also using Vyleesi may arrive in the perioperative setting with subtherapeutic naltrexone levels, which could affect postoperative opioid dosing calculations. The FDA drug interaction data summary advises avoiding concurrent use of oral naltrexone and bremelanotide, but the perioperative implication of residual interaction effects deserves direct communication between the prescriber and the surgical team.

Indomethacin, a commonly used perioperative NSAID for procedures such as laparoscopic gynecologic surgery, does not appear in the bremelanotide interaction database. However, a 2019 clinical pharmacology review in CPT: Pharmacometrics and Systems Pharmacology notes that melanocortin receptor agonism may modify prostaglandin pathways in ways that are not yet fully characterized, suggesting that the interaction field for this drug class is still being defined.

Telehealth Prescribing Considerations

Bremelanotide is frequently prescribed through telehealth platforms, including HealthRX. That model creates a specific communication gap: the prescribing clinician may not be the same person managing surgical care, and routine pharmacy records may not flag Vyleesi to a surgeon's preoperative pharmacist review because it is an injectable rather than an oral tablet.

The FDA's guidance on patient medication safety communications recommends that patients maintain an up-to-date medication list including injectables, patches, and devices. Telehealth prescribers should include a standard discharge instruction reminding bremelanotide users to disclose the medication to any surgical team and to observe the 24-hour hold window.

The American Society of Health-System Pharmacists guidelines on medication reconciliation specifically identify injectable peptide hormones as a high-risk category for omission from perioperative medication lists, a gap that telehealth prescribers are well-positioned to close through proactive patient education at the time of initial prescription.